Non-Hodgkin Lymphoma

Prognostic factors for hematotoxicity of chemotherapy in aggressive non-Hodgkin's lymphoma.

BACKGROUND: Little is known on the heterogeneity of hematotoxicity in patients receiving multicycle chemotherapy. PATIENTS AND METHODS: We analyzed data of 1399 patients with aggressive lymphoma from trials using CHOP (combination chemotherapy with cyclophosphamide, doxorubicin, vincristine and prednisone)-like therapies.